Strong Cellular Immune Response, but Not Humoral, against SARS-CoV-2 in Oncohematological Patients with Autologous Stem Cell Transplantation after Natural Infection.

J Clin Med · 2022 · PMC9032116 · PMID 35456230

Europe PMC DOI

hedged sentence

0.0592

closest p · 1.2× alpha

0.0592

boldest claim

The sentences

almost significantp = 0.0592so close (0.05 < p ≤ 0.1)

Enhanced ADCC Activity in PBMCs from Oncohematological Individuals after ASCT Antibody-mediated cytotoxic activity against rituximab-coated Raji cells of peripheral blood lymphocytes (PBMCs) from oncohematological patients was increased 2.1-fold on average after ASCT, in comparison with healthy donors who recovered from mild COVID-19 ( Figure 3 ), but this difference was almost significant ( p = 0.0592). 3.5.

also in 1,858 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.